ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3199-Frankston-PASO-Medical
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
5
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07365319
Advanced
Phase 2 / Phase 3
Recruiting
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (
TeLuRide-008
).
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
Squamous non-small-cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - PASO Medical
NCT07262619
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Na\xEFve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - PASO Medical
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT07158918
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors (
ABL103-1002
)
anti-PD-1 monoclonal antibody
bispecific B7H4/4-1BB antibody
Solid tumour
VIC
3199 - Frankston - PASO Medical
NCT06907043
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors (
EIK1004-001
)
PARP1-selective inhibitor
Solid tumour
VIC
3199 - Frankston - PASO Medical
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Not yet recruiting (1)
Recruitment Country and State
VIC (5)
NSW (3)
SA (1)
NZ (1)
Phase
Phase 1 / Phase 2 (4)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (5)
Cancer Therapy Class
PD-1
60%
PD-1/PD-L1
60%
EGFR
20%
KRAS
20%
TLR7/TLR8
20%
WRN
20%
4-1BB
20%
B7H4
20%
PARP
20%
PARP1-selective
20%
Facility
3199 - Frankston - PASO Medical (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2109 - North Ryde - Macquarie University Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3066 - Epping - Northern Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Upper gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Squamous non-small-cell lung cancer
Thoracic cancer
Biomarker-defined solid tumour
Colorectal adenocarcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Gynaecological cancer
Lower gastrointestinal cancer
MSI-H/dMMR solid tumour
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
dMMR solid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy